Discontinued — last reported Q3 '22
BSX Reportable Segments — Net Sales
Boston Scientific BSX Reportable Segments — Net Sales decreased by 2.3% to $3.17B in Q3 2022 compared to the prior quarter. Year-over-year, this metric grew by 8.1%, from $2.93B to $3.17B. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption of the company's medical device portfolio and effective commercial execution, while a decrease may signal competitive pressure, pricing challenges, or reduced demand for elective procedures.
Detailed definition
This metric represents the total revenue generated from the sale of medical devices and related services within the comp...
Peer comparison
Comparable to segment-level revenue reporting for diversified medical device manufacturers like Medtronic or Abbott Laboratories, where performance is tracked by therapeutic area or business unit.
bsx_segment_bsx_reportable_segments_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | |
|---|---|---|---|---|---|---|
| Value | $3.08B | $2.93B | $3.13B | $3.03B | $3.24B | $3.17B |
| QoQ Change | — | -4.7% | +6.7% | -3.2% | +7.2% | -2.3% |
| YoY Change | — | — | — | — | +5.4% | +8.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's bsx reportable segments — net sales?
- Boston Scientific (BSX) reported bsx reportable segments — net sales of $3.17B in Q3 2022.
- How has Boston Scientific's bsx reportable segments — net sales changed year-over-year?
- Boston Scientific's bsx reportable segments — net sales increased by 8.1% year-over-year, from $2.93B to $3.17B.
- What does bsx reportable segments — net sales mean?
- The total revenue generated by the company's core medical device business segments.